Dr. Olencki is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
320 W 10th Ave
Columbus, Ohio
Columbus, OH 43210Phone+1 614-293-9868Fax+1 614-293-7525
Education & Training
Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 1984 - 1985
Corewell Health East Beaumont (Royal Oak)Residency, Internal Medicine, 1981 - 1984
Michigan State University College of Osteopathic MedicineClass of 1980
Certifications & Licensure
OH State License 1993 - 2021
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma
- Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia Start of enrollment: 2007 Nov 01
- PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer Start of enrollment: 2008 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- 361 citationsNCCN clinical practice guidelines in oncology: kidney cancer.Robert J. Motzer, Neeraj Agarwal, Clair J. Beard, Graeme B. Bolger, Barry Boston
Journal of the National Comprehensive Cancer Network. 2009-06-01 - 128 citationsNCCN clinical practice guidelines in oncology: testicular cancer.Robert J. Motzer, Neeraj Agarwal, Clair J. Beard, Graeme B. Bolger, Barry Boston
Journal of the National Comprehensive Cancer Network. 2009-06-01 - 124 citationsF-18 Fluorodeoxyglucose Positron Emission Tomography in the Evaluation of Distant Metastases From Renal Cell CarcinomaNavneet S. Majhail, Jean-Luc Urbain, Justin M. Albani, Mangesh H. Kanvinde, Thomas W. Rice
Journal of Clinical Oncology. 2003-11-01
Journal Articles
- Corrigendum to ‘Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised ...Toni K Choueiri, Olwen Hahn, Thomas Olencki, Eric J Small, Shaker Dakhil, Darren R Feldman, European Journal of Cancer
Authored Content
- Corrigendum to ‘Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-Free Survival by Independent Review and Overall Survival Update’ [Eur J Cancer 94 (May 2018) 115–125]September 2018
- Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-Free Survival by Independent Review and Overall Survival UpdateApril 2018
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
